Clinical Trials Browser

Terminated × INDUSTRY × dalotuzumab × Clear all

NCT01609231 2020-05-04

MK-0646-025

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1 Terminated

47 enrolled 12 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms